Allergic contact dermatitis to topical prodrugs used in photodynamic therapy

Helen Cordey (Lead / Corresponding author), Sally Ibbotson

Research output: Contribution to journalLetter

3 Citations (Scopus)
87 Downloads (Pure)

Abstract

Topical photodynamic therapy (PDT) is a well-established treatment for actinic keratosis, Bowen's disease and superficial basal cell carcinoma and its use has also been explored for a variety of other indications.(1,2,3) Treatment involves application of a pro-drug (either 5-aminolaevulinic acid (ALA) or its methlyester, methylaminolevulinate (MAL)) which is preferentially taken up by dysplastic or neoplastic cells and converted into the active photosensitiser protoporphyrin IX (PPIX). Subsequent activation of PPIX by red light results in the production of cytotoxic oxygen species, inflammation and relatively selective diseased tissue destruction. This article is protected by copyright. All rights reserved.

Original languageEnglish
Pages (from-to)320-322
Number of pages3
JournalPhotodermatology, Photoimmunology & Photomedicine
Volume32
Issue number5-6
Early online date7 Jul 2016
DOIs
Publication statusPublished - 15 Aug 2016

Fingerprint

Allergic Contact Dermatitis
Photosensitizing Agents
Photochemotherapy
Prodrugs
Bowen's Disease
Actinic Keratosis
Aminolevulinic Acid
Basal Cell Carcinoma
Oxygen
Inflammation
Light
Therapeutics
protoporphyrin IX

Cite this

@article{c0fdfd29ed294d498cbc5db33030f261,
title = "Allergic contact dermatitis to topical prodrugs used in photodynamic therapy",
abstract = "Topical photodynamic therapy (PDT) is a well-established treatment for actinic keratosis, Bowen's disease and superficial basal cell carcinoma and its use has also been explored for a variety of other indications.(1,2,3) Treatment involves application of a pro-drug (either 5-aminolaevulinic acid (ALA) or its methlyester, methylaminolevulinate (MAL)) which is preferentially taken up by dysplastic or neoplastic cells and converted into the active photosensitiser protoporphyrin IX (PPIX). Subsequent activation of PPIX by red light results in the production of cytotoxic oxygen species, inflammation and relatively selective diseased tissue destruction. This article is protected by copyright. All rights reserved.",
author = "Helen Cordey and Sally Ibbotson",
note = "This article is protected by copyright. All rights reserved.",
year = "2016",
month = "8",
day = "15",
doi = "10.1111/phpp.12252",
language = "English",
volume = "32",
pages = "320--322",
journal = "Photodermatology, Photoimmunology & Photomedicine",
issn = "0905-4383",
publisher = "Wiley",
number = "5-6",

}

Allergic contact dermatitis to topical prodrugs used in photodynamic therapy. / Cordey, Helen (Lead / Corresponding author); Ibbotson, Sally.

In: Photodermatology, Photoimmunology & Photomedicine, Vol. 32, No. 5-6, 15.08.2016, p. 320-322.

Research output: Contribution to journalLetter

TY - JOUR

T1 - Allergic contact dermatitis to topical prodrugs used in photodynamic therapy

AU - Cordey, Helen

AU - Ibbotson, Sally

N1 - This article is protected by copyright. All rights reserved.

PY - 2016/8/15

Y1 - 2016/8/15

N2 - Topical photodynamic therapy (PDT) is a well-established treatment for actinic keratosis, Bowen's disease and superficial basal cell carcinoma and its use has also been explored for a variety of other indications.(1,2,3) Treatment involves application of a pro-drug (either 5-aminolaevulinic acid (ALA) or its methlyester, methylaminolevulinate (MAL)) which is preferentially taken up by dysplastic or neoplastic cells and converted into the active photosensitiser protoporphyrin IX (PPIX). Subsequent activation of PPIX by red light results in the production of cytotoxic oxygen species, inflammation and relatively selective diseased tissue destruction. This article is protected by copyright. All rights reserved.

AB - Topical photodynamic therapy (PDT) is a well-established treatment for actinic keratosis, Bowen's disease and superficial basal cell carcinoma and its use has also been explored for a variety of other indications.(1,2,3) Treatment involves application of a pro-drug (either 5-aminolaevulinic acid (ALA) or its methlyester, methylaminolevulinate (MAL)) which is preferentially taken up by dysplastic or neoplastic cells and converted into the active photosensitiser protoporphyrin IX (PPIX). Subsequent activation of PPIX by red light results in the production of cytotoxic oxygen species, inflammation and relatively selective diseased tissue destruction. This article is protected by copyright. All rights reserved.

U2 - 10.1111/phpp.12252

DO - 10.1111/phpp.12252

M3 - Letter

VL - 32

SP - 320

EP - 322

JO - Photodermatology, Photoimmunology & Photomedicine

JF - Photodermatology, Photoimmunology & Photomedicine

SN - 0905-4383

IS - 5-6

ER -